Kestra Medical Technologies (NASDAQ:KMTS) Receives “Buy” Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $32.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company upped their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a research note on Friday, January 16th. Finally, Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.80.

Kestra Medical Technologies Trading Up 0.9%

Shares of Kestra Medical Technologies stock opened at $19.49 on Tuesday. The firm has a 50-day simple moving average of $23.02 and a two-hundred day simple moving average of $24.55. The company has a market cap of $1.14 billion and a P/E ratio of -4.92. Kestra Medical Technologies has a fifty-two week low of $13.25 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.Kestra Medical Technologies’s quarterly revenue was up 62.7% on a year-over-year basis.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total transaction of $304,050.00. Following the completion of the sale, the insider owned 364,786 shares of the company’s stock, valued at $7,394,212.22. The trade was a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 over the last three months. 3.60% of the stock is owned by insiders.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Invesco Ltd. purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at about $239,000. Perceptive Advisors LLC purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at about $7,558,000. Janus Henderson Group PLC purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at about $300,000. Balyasny Asset Management L.P. grew its stake in Kestra Medical Technologies by 80.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock valued at $183,000 after acquiring an additional 3,086 shares in the last quarter. Finally, Burkehill Global Management LP purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at about $1,326,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.